Bolt Biotherapeutics (BOLT) Misses Q2 EPS by 124c
Tweet
Share
E-mailGet Alerts BOLT Hot Sheet
Join SI Premium – FREE
Bolt Biotherapeutics (NASDAQ: BOLT) reported Q2 EPS of ($4.57), $1.24 worse than the analyst estimate of ($3.33). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $1.5 million.
For earnings history and earnings-related data on Bolt Biotherapeutics (BOLT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- X Financial (XYF) Tops Q2 EPS by 438c
- Amarin to present REDUCE-IT analyses at ESC Congress 2026
- Mackay Gold & Silver acquires Comstock Nevada mining assets
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
